TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Pediatric Igel Airway in 250 Children

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* All children weighing 5 -30kg~* Classified by the American Society of Anesthesiology (ASA) as grade 1-2,~* Scheduled for elective surgery under general anaesthesia, in whom a LMA or PLMA would otherwise be used for airway maintenance and in whom neuromuscular blocking drugs will not be used.~Exclusion Criteria:~* Inability of patient or parents to understand the study or consent process~* Neck pathology~* Previous or anticipated airway problems~* Pathology of airway, respiratory tract, upper gastrointestinal tract~* Increased risk of regurgitation or aspiration~* Weight \>30kg or \<5 kg~* ASA 3 and above,~* Emergency surgery

- Gender: ALL
- Minimum Age: None
- Maximum Age: 16 Years
- Healthy Volunteers: t

Study Arms:
- Children (Type: None): between 10 and 30 kgs
- Infants (Type: None): between 5 - 10 kg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of Omega-3 Supplementation for Children With Language Impairments

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* children in the chronological age range of 24 to 42 months at the time of initial assessment~* diagnosis of expressive, receptive or mixed language impairment (LI) by a certified Speech-Language Pathologist (S-LP)~* ability to take daily omega-3 supplementation (with caregiver assistance)~Exclusion Criteria:~* children with any organic disease processes or genetic syndromes, or known developmental disorders such as autism that may present with language impairment~* children with hearing impairment~* children who take any non-standard dietary supplements (i.e., apart from multi-vitamins), particularly any omega-3 FA, prior to starting the study~* children whose parents do not have an adequate understanding of English or French

- Gender: ALL
- Minimum Age: 24 Months
- Maximum Age: 42 Months
- Healthy Volunteers: f

Study Arms:
- Omega-3 (Type: EXPERIMENTAL): Treatment arm, using the omega-3 product (fish oil/paste)
- Control (Type: PLACEBO_COMPARATOR): Placebo is a paste of non-omega-3 (plant based) oil with a taste/flavour identical to intervention paste

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Feasibility of a Supportive Education Program for Latina Breast Cancer Survivors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
The population will consist of Latinas with breast cancer who have completed primary cancer treatment. A total of 10 subjects will be accrued.~Inclusion Criteria:~* Diagnosis of Stage I, II or III.~* Self-identification as Hispanic/Latina.~* Able to read and understand English or Spanish to participate in the education sessions.~* Ability to read and/or understand the study protocol requirements, and provide written informed consent~* Subjects maybe be on hormonal therapy after treatment for initial breast cancer.~Exclusion Criteria:~* Actively receiving treatment with surgery, radiation therapy, or chemotherapy.~* Patients who have recurrence, metastasis, or a second primary cancer

- Gender: FEMALE
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Supportive Care (BBCEI) (Type: EXPERIMENTAL): Participants undergo 2 tailored BBCEI sessions within 1 month. At the beginning of the first session the research nurse will present the participants with a list of common physical and social concerns. The participant will then be asked to identify 3 topics that she wants to discuss. The research nurse will discuss with the participant any relevant supportive care resources and make the appropriate referrals. At the second session the focus of the BBCEI will be on psychological and spiritual well-being.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Treating Adolescents With CBT and OBH

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Between the ages of 13 and 17 years of age~* 5th grade reading level~* For minors, informed assent~* Parental informed consent and adult consent to participate in the study~* Current diagnosis of Depression and/or Anxiety per parent report, parental interview, and score of 65 on the RCADS. Youth with comorbid diagnoses of these listed diagnoses are eligible~* Current secondary diagnosis of Substance Use Disorder (optional)~* Score greater than a 47 on the YoQ-2.0~* Willingness to participate in all aspects of the treatment programs~* Has the ability to carry a pack that is 1⁄4 their body weight~Exclusion Criteria:~* Primary Diagnosis of Substance Use Disorder~* Antisocial Personality~* Level 2 or higher Autism Spectrum~* Schizophrenia~* Actively suicidal~* Eating disorders~* BMI greater than 34~* Diabetic~* Physical ailments or disabilities limiting person from hiking, camping, backpacking~* Specific medications including Anxiolytics/Benzodiazepines, Opiates, or multiple Antipsychotics and Mood Stabilizers~* Youth who have a positive pregnancy test~* Participation in another treatment or intervention study within one year of beginning the study~* Individuals currently suffering from detoxification as a result of drug use in the last five days. If drug use occurs during this time period, the participant must wait until they have achieved five days of substance free behavior. This is done to prevent contraindications of treatment (e.g., interaction between drugs and the environment)~* Currently practicing violent behaviors to self or others within the past year per Parent Report~* Currently experiencing hallucinations (hearing voices or seeing things that are not there)

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Outdoor Behavioral Healthcare (OBH) (Type: EXPERIMENTAL): Adolescent participants will be asked to complete an intervention in either an OBH program (90 days) or a CBT (12 weeks) program. Parent/guardians and adolescent participants will be asked to complete several surveys before and during the program, and up to one year after.
- Cognitive Behavioral Therapy (CBT) (Type: EXPERIMENTAL): Adolescent participants will be asked to complete an intervention in either an OBH program (90 days) or a CBT (12 weeks) program. Parent/guardians and adolescent participants will be asked to complete several surveys before and during the program, and up to one year after.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Remifentanil in Ventilated Preterm Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* preterm infants (\<37weeks of gestational age)~* requiring ventilator care~* informed consent~Exclusion Criteria:~* major anomaly~* 48hrs after birth~* requiring operation during drug infusion~* cord blood pH \< 7.0~* intraventricular hemorrhage grade III or more~* investigators decision

- Gender: ALL
- Minimum Age: None
- Maximum Age: 48 Hours
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 5% dextrose infusion for 72 hours during ventilator care start within 48 hours after birth
- remifentanil (Type: ACTIVE_COMPARATOR): 0.1mcg/kg/min remifentanil infusion for 72 hours during ventilator care start within 48 hours after birth

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pain Outcomes After Anterior Cruciate Ligament Reconstruction With Posterior Capsular Marcaine Injection

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult individuals (ages 18-60), both sexes, submitted to elective ACL reconstructions with or without partial menisectomies of the medial or lateral meniscus~Exclusion Criteria:~* Multiligamentous injury or revision surgery~* Known narcotic/substance abuse or regular opiate use~* Known allergy to any medication or anesthetic being used in this study~* Patients with pre-existing diabetic or femoral neropathy~* INTRAOPERATIVELY- if chrondral microfractures, inside-out or outside-in meniscal repairs were performed (\*\*\*Since these additional surgeries within the joint may increase the perceived level of pain post-op\*\*\*)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- No Injection (Type: PLACEBO_COMPARATOR): These patients will receive standard of care when undergoing anterior cruciate ligament reconstruction and will NOT be receiving a posterior capsular knee injection of Marcaine 0.5%.~They will be monitored for pain control and pill intake while in the PACU and the first four days post-operatively the same as the patients in the INJECTION Arm of the study.
- Injection (Type: EXPERIMENTAL): These patients will receive standard of care when undergoing anterior cruciate ligament reconstruction but will additionally be receiving a one-time posterior capsular knee injection of Marcaine 0.5% (20cc) during the surgery.~They will be monitored for pain control and pill intake while in the PACU and the first four days post-operatively the same as the patients in the NO injection Arm of the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Effectiveness of a Omega-3 Enriched Supplement on Chemotherapy Tolerance in Colon Cancer Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed of metastatic colon adenocarcinoma that are going to receive first line chemotherapy treatment in the oncology day hospital.~* Age over 18 years old.~Exclusion Criteria:~* Patients diagnosed of colon cancer are receiving second line chemotherapy.~* Antecedents of other malignant tumors with the exception of basocellular epithelioma.~* Chronic renal failure (Creatinine \> 1.7).~* Previous diabetes mellitus.~* Obesity (IMC \> 30)~* Medical conditions that imply hepatic encephalopathy, or ascites.~* Severe malnutrition according to the classification of the Subjective Global Assessment (SGA) or a BMI \< 16.5.~* Major psychiatric disorder.~* Patients receiving enteral or parenteral nutrition.~* Contraindications for the indication of the nutritional supplement: Galactosemia.~* Seafood or seafood byproducts allergy.~* Patients taking drugs that affect the metabolism (anabolic steroids, orexigenic agents...).~* Absence of the informed consent form signed by the patient.~* Any patient who has disability to comply with the treatment or who has inability according to the researcher.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Eicosapentaenoic acid enriched nutritional supplement (Type: EXPERIMENTAL): None
- No supplementation (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Renal Denervation in Patients With Chronic Heart Failure & Renal Impairment Clinical Trial

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Heart Failure patients NYHA Class II or III~* Renal Impairment Left Ventricular Ejection Function \<40%~* GFR 30 to 75 mL/min/1.73m2~* Optimal stable medical therapy~Exclusion Criteria:~* Renal artery anatomy must be eligible for treatment as determined by Angiography, and~* History of prior renal artery intervention~* Single functioning kidney.~* Myocardial Infarction, unstable angina pectoris or cerebrovascular Accident within 3 months~* Systolic BP \< 90 mmHG

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: OTHER): Renal Denervation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Prospective Cohort of Kidney Transplanted Patients Receiving an Extended Releasing Tacrolimus-Everolimus Association

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients over 18 years old~* Patients informed and giving his agreement to the use of every collected data~* Patients with kidney transplantation for at least one year and being treated with the immunosppressive assiociation of Tacrolimus (Prograf ®)-Everolimus~* Patients whose investigators decides to switch from Prograf ® to an Envarsus ®-Everolimus association~Exclusion Criteria:~* Other transplantation~* Drug or alcohol abuse~* Patients unable to understand the purpose or modalities of this study, unable to give his agreement or unable to stick to the protocol~* Patients on an interventionnal protocol when included

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TREVISE (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Antiretroviral Treatment on Pharmacokinetics and Pharmacodynamics of Thienopyridines in Healthy Volunteers and HIV Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males \>18 years~* Understanding of French language and able to give an inform consent~* Anti-HIV therapy with ritonavir or cobicistat (for HIV group)~* Stable antiretroviral treatment since at least 2 weeks (for HIV group)~* Viremia \<100 copies/ml (for HIV group)~Exclusion Criteria:~* renal failure: calculated creatinine Clearance (cockcroft) \< 50ml/min~* hepatic impairment (ASAT, ALAT, bilirubin, gamma-GT more than 2-fold increase)~* smoker \>1 pack/day~* hypersensitivity to any of the drugs used~* intake of any drug or particular food (grapefruit) that can affect CYP activities inhibitors (in the last 10 days before the start of the study or 4 half-life after the last intake)~* pathologies or drugs associated with an increased bleeding risk such as aspirin, non-steroidal anti-inflammatory drugs, steroids and serotonin reuptake inhibitors (in the last 10 days before the start of the study or 4 half-life after the last intake)~* bleeding familial history or antecedent or haemorrhagic disease

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- HIV clopidogrel (Type: EXPERIMENTAL): clopidogrel 300 mg single dose oral route
- HIV prasugrel (Type: EXPERIMENTAL): prasugrel 60 mg single dose oral route
- Control clopidogrel (Type: ACTIVE_COMPARATOR): clopidogrel 300 mg single dose oral route
- Control prasugrel (Type: ACTIVE_COMPARATOR): prasugrel 60 mg single dose oral route

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Aspirin for Venous Ulcers: Randomised Trial (AVURT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Those with at least one chronic venous leg ulcer - where chronic venous leg ulceration is defined as any break in the skin which has either: a) been present for more than six weeks, or b) occurred in a person with a history of venous leg ulceration. Ulcers will be considered purely venous if clinically no other etiology was suspected. For this the ulcer must be venous in appearance (i.e. moist, shallow, of an irregular shape) and lie wholly or partially within the gaiter region of the leg. If the patient has more than one ulcer we will choose the largest ulcer as the 'index' lesion for purposes of the analysis.~* Ulcer area \> 1 square cm~* Participants must have had an ankle brachial pressure index (ABPI) ≥ 0.8 taken within the previous three months. When the ABPI is incompressible other forms of assessment including peripheral pulse examination / toe pressure / duplex ultrasound in combination with clinical judgement to be used to exclude PAD~* Aged ≥ 18 years (no upper age limit)~* Able and willing to provide informed consent~* Ulcer duration \> 6 weeks or prior history of venous ulceration.~Exclusion Criteria:~* Unable to provide consent~* Unwilling to provide consent~* Foot (below the ankle) ulcer~* A leg ulcer of non-venous aetiology (i.e. arterial)~* Ankle-brachial pressure index (ABPI) \<0.8~* Current regular use of aspirin (as may be randomised to placebo)~* Previous intolerance of aspirin / contraindication to aspirin (decision made according to the prescribers' clinical judgement)~* Prohibited medication: Probenecid~* Known lactose intolerance (as placebo contains lactose)~* Pregnant/lactating women~* Currently participating in another study evaluating leg ulcer therapies.~* Another reason that excluded them from participating within this trial (decision made according to the nurses' or prescribers' clinical judgment )\*~* Previously been recruited in to this trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aspirin (Type: EXPERIMENTAL): Aspirin 300mg capsule by mouth once a day for 24 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Placebo capsule (for aspirin 300mg capsule) by mouth once a day for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PET/MR in Surgical Planning for Breast CA Treated With Neoadj Chemo

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years of age (no upper age limit)~* Signed, IRB-approved written informed consent~* Must have clinical T1-3, N0-3, M0 disease. All phenotypes are acceptable..~* Must have surgically curable disease as evaluated by the UNC Multidisciplinary Tumor Board.~* Must have pre- and post-treatment MRI imaging as part of the treatment plan.~* Must be able to meet size restrictions for the PET-MR scanner: chest depth and abdominal depth less than 27 cm (approximately the smallest 55% of women will meet this), as measured on imaging or with physical template.~* Must be in acceptable health to undergo chemotherapy and curative intent surgery as assessed by Multidisciplinary Tumor Board.~* Must be able to understand and comply with study procedures for the entire length of the study.~* Must receive their chemotherapy and curative intent surgery at UNC Hospitals. -If patient has a history of prior malignancy, including melanoma, patient must be cancer- free for three or more years. Non-melanoma skin cancers will be included even if not cancer-free for three years.~* Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to each PET/MRI~Exclusion Criteria:~* Inability to tolerate MRI (e.g., inability to lie flat for \>1 hour)~* Presence of pacemaker, intracranial aneurysm clip, bladder stimulator, cochlear implant or metal near eyes or near pelvis that would create excessive imaging artifact~* Poorly controlled diabetes mellitus~* Patient receiving neoadjuvant endocrine therapy (due to low likelihood of complete response)~* Pregnancy or lactating female~* Substance abuse, medical, psychological, or social conditions that may interfere with the patient's participation in the study~* Evidence of distant disease on physical exam or initial imaging~* Medical conditions precluding chemotherapy or curative intent surgery~* Incarcerated or otherwise institutionalized at time of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PET/MR (Type: EXPERIMENTAL): Each patient will undergo two combined PET/MR scans. The pre-treatment and post-treatment combined PET/MR scans are for research purposes and not part of the patient's standard of care.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues